Evidence map›Paper›PMID 37446161›Full record

ReviewInternational journal of molecular sciences2023

Receptor for the Advanced Glycation End Products (

Klaudia Gutowska, Krzysztof Czajkowski, Alina Kuryłowicz

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Klaudia GutowskaII Faculty and Clinic of Obstetrics and Gynaecology, Medical University of Warsaw, 00-315 Warsaw, Poland.ORCID 0000-0002-1291-0920
Krzysztof CzajkowskiII Faculty and Clinic of Obstetrics and Gynaecology, Medical University of Warsaw, 00-315 Warsaw, Poland.
Alina KuryłowiczDepartment of Human Epigenetics, Mossakowski Medical Research Centre PAS, 02-106 Warsaw, Poland.ORCID 0000-0001-8632-4927
Medical University of Warsaw · PLPostgraduate School of Molecular Medicine · PL

Funding

National Science Centre Poland 2018/31/B/NZ5/01556
6 · The paper itself

Abstract

Advanced glycation end products (AGEs) are mediators in the process of cellular dysfunction in response to hyperglycemia. Numerous data indicate that the accumulation of AGEs in the extracellular matrix plays a key role in the development of obesity-related adipose tissue dysfunction. Through binding of their membrane receptor (

Indexed as

Adipose TissueGlycation End Products, AdvancedAnimalsHumansObesityReceptor for Advanced Glycation End ProductsSignal TransductionGlycation End Products, AdvancedReceptor for Advanced Glycation End Productsadipose tissue dysfunctionadvanced glycation end products (AGEs)cardiovascular diseasesdiabetesinsulin resistancemetabolic inflammationobesityreceptor for AGE (RAGE)

Identifiers

PMID37446161
PMCPMC10341816
OpenAlexW4382981961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.